Avacta Group plc earnings date
Avacta Group plc (RTQ1) Q4 2025 Earnings Report
DE:RTQ1 Q4 2025 EPS Results
- Actual EPS
- -EUR 0.06
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- ―
DE:RTQ1 Q4 2025 Revenue Results
- Actual Revenue
- EUR 66.73K
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 05/19/2026
- Time
- Before Open
- Conference Call
- Tuesday, May 19, 2026
Avacta Group plc's next earnings date is estimated for April 22, 2027, based on past reporting schedules.
Q4 2025 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2025 Earnings Call Summary
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.
The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.
- Clinical Milestone — AVA6103 First Patient DosedFirst patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
- Encouraging AVA6000 Clinical Progress and Regulatory OutcomeAVA6000 (Gen One) reported preliminary efficacy and safety in salivary gland cancer; Phase Ib continues with a recommended dose for expansion (RDE) defined at 310 mg/m2; favorable cardiac safety data resulted in lifting of the lifetime maximum doxorubicin dose constraint.
- Strong Preclinical Differentiation vs ADCsPreclinical translational data show up to ~40x higher tumor Cmax for released exatecan (AVA6103) versus comparator ADC payloads and ~3x higher tumor selectivity index (tumor vs plasma) — key mechanistic advantages that may translate clinically.
- Increased R&D Investment Reflecting Pipeline FocusResearch & development spend rose to GBP 18.8m in FY2025 from GBP 14.3m prior year, a ~31.5% increase, reflecting focused investment in the proprietary pre|CISION peptide drug conjugate platform and therapeutic programs.
- Improved Cost Efficiency in Administration and Cash OutflowsAdministrative expenses fell to ~GBP 10m from GBP 12m (~16.7% reduction). Net operating cash outflows improved to GBP 22.64m from GBP 24.94m (~9.2% reduction year-on-year).
- Fundraising and Cash PositionRaised GBP 32.5m over the last 18 months (including an oversubscribed placing/subscription of GBP 10m); cash at end-April 2026 was GBP 16.4m, extending runway into early Q1 2027 (projection excludes partnering income).
- Pipeline & IP Expansion — Gen Two and Gen Three ProgressUpdated in vivo data for Gen Two (AVA6103) and Gen Three (AVA6207 dual-payload) at AACR; continued growth of IP estate protecting sustained release and dual-payload technologies; dual-payload capability is a novel differentiator.
DE:RTQ1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 22, 2027 | 2026 (Q4) | ―- | -0.06 | ― | ― |
| Sep 30, 2026 | 2026 (Q2) | ―-0.05 | -0.05 | 0.00% (+0.00) | |
| May 19, 2026 | 2025 (Q4) | ―-0.06 | ― | ― | |
| Sep 30, 2025 | 2025 (Q2) | ―-0.05 | -0.04 | -10.53% (-0.00) | |
| Jun 06, 2025 | 2024 (Q4) | ―- | -0.06 | ― | |
| Sep 30, 2024 | 2024 (Q2) | ―-0.04 | -0.05 | 11.63% (+0.01) | |
| Apr 30, 2024 | 2023 (Q4) | ―-0.06 | -0.14 | 57.76% (+0.08) | |
| Sep 28, 2023 | 2023 (Q2) | ―-0.05 | -0.04 | -19.44% (-0.01) | |
| Apr 25, 2023 | 2022 (Q4) | -0.06-0.14 | -0.07 | -81.25% (-0.06) | |
| Sep 29, 2022 | 2022 (Q2) | ―-0.04 | -0.05 | 12.20% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

